Delving into the Latest Updates on DXC-006 with Synapse

Overview

Basic Info

Drug Type

Antibody drug conjugate (ADC)

Synonyms

DXC 006, DXC-006

Target

CD56

Mechanism

CD56 inhibitors(Neural cell adhesion molecule 1 inhibitors)

Therapeutic Areas

NeoplasmsHemic and Lymphatic DiseasesImmune System Diseases+ [3]

Active Indication

Multiple MyelomaAdvanced Malignant Solid NeoplasmHematologic Neoplasms+ [2]

Inactive Indication-

Originator Organization

Hangzhou DAC Biotechnology Co., Ltd.

Active Organization

Hangzhou DAC Biotechnology Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, MTD, DLT, RP2D, the PK characteristics, preliminary anti-tumor activity, the immunogenicity of DXC006 in patients with a variety of solid tumors, including small cell lung cancer, multiple myeloma, and neuroblastoma, and hematological malignancies.

Start Date24 Jan 2024

Sponsor / Collaborator

Hangzhou DAC Biotechnology Co., Ltd.

ChiCTR2400079372 / SuspendedPhase 1IIT

An open-label dose escalation and cohort expansion phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics and and efficacy of DXC006 in patients with advanced solid tumors and hematologic malignancies

Start Date02 Jan 2024

Sponsor / Collaborator

Sun Yat-Sen University Cancer Center

CTR20234095 / Not yet recruitingPhase 1

评估注射用DXC006在多种实体瘤、血液瘤患者中的安全性、耐受性、药代动力学特征以及初步疗效的开放、多中心、首次人体、剂量递增和扩大入组的I期临床研究。

[Translation] An open, multicenter, first-in-human, dose-escalation and expanded Phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of DXC006 for injection in patients with various solid tumors and hematological tumors.

评估注射用DXC006在多种实体瘤、血液瘤患者中的安全性、耐受性、药代动力学特征以及初步疗效的开放、多中心、首次人体、剂量递增和扩大入组的I期临床研究

[Translation]

An open, multicenter, first-in-human, dose-escalation and expanded Phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of DXC006 for injection in patients with various solid tumors and hematological tumors

Start Date-

Sponsor / Collaborator

Hangzhou DAC Biotechnology Co., Ltd.

100 Clinical Results associated with DXC-006

Login to view more data

100 Translational Medicine associated with DXC-006

Login to view more data

100 Patents (Medical) associated with DXC-006

Login to view more data

100 Deals associated with DXC-006

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Multiple Myeloma	Phase 1	-	Hangzhou DAC Biotechnology Co., Ltd.	24 Jan 2024
Advanced Malignant Solid Neoplasm	Phase 1	CN	Hangzhou DAC Biotechnology Co., Ltd.	15 Dec 2023
Hematologic Neoplasms	Phase 1	CN	Hangzhou DAC Biotechnology Co., Ltd.	15 Dec 2023
Neuroblastoma	Preclinical	CN	Hangzhou DAC Biotechnology Co., Ltd.	22 Mar 2024
Small Cell Lung Cancer	Preclinical	CN	Hangzhou DAC Biotechnology Co., Ltd.	22 Mar 2024